***Background.*** Vancomycin (V) is the mainstay for treatment of infections caused by MRSA. Yet failures of therapy with V are common. Current guidelines recommend V alone for treatment of most serious infections. Exceptions include prosthetic valve endocarditis and in some instances osteomyelitis and CNS infections where combinations of antibiotics are suggested.

***Methods.*** We used timed kill-curves to test antibiotic combinations used in our center against six isolates of MRSA. These six with V MICs of 2 confirmed by Microscan and E-test were chosen from 15 blood isolates of MRSA saved over three years. We used V and gentamicin (G), V and rifampin (R), two combinations used to treat MRSA, and V and cefazolin (C), a combination recommended in recent publications. Colonies were counted in duplicate at 0, 4, 8, 12 and 24 hour time points. Determinations of synergy, indifference and antagonism were made at the 24 hour time point. Standard definitions requiring 2 log differences in cfu/mL were used.

***Results.*** Results are shown in the following table:

  Combination   Synergy   Indifferent   Antagonistic
  ------------- --------- ------------- --------------
  V + G         0         6             0
  V + R         0         5             1
  V + C         0         6             0

Antibiotic synergy was not demonstrated with any of the combinations tested. In all but one experiment, the combination was "indifferent," however V + G was more active than V alone for three strains. Although "antagonistic" in only one, V+ R was less active than either drug alone for four of the isolates. Killing with V + C paralleled killing with V alone in all six strains.

***Conclusion.*** We have shown that combining G, R or C with V against six bloodstream isolates of MRSA with V MIC of 2 is not synergistic *in vitro.* These results did show enhanced killing with V + G in three strains and with V + R in one strain. Killing with V + R was slightly worse in three and significantly worse in one of the isolates. These results, although not showing synergy, may support the use of V + G, and, although not showing antagonism, do not support use of V + R.
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